CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The ADVOS therapy system aims to improve survival rates for COVID-19 patients experiencing severe multi-organ failure by providing comprehensive support for liver, lung, and kidney functions. This low-invasive device enhances blood purification and pH correction, potentially saving lives in intensive care settings.
ADVITOS` innovation – the ADVOS therapy system - has the potential to increase the survival of COVID-19 patients suffering from severe multi organ failure (MOF).
First published clinical data show that ADVOS improves survival by up to 30% in critically ill patients on intensive care.
The first COVID-19 patient with MOF is being treated with ADVOS in Germany at present with promising results. ADVITOS is a SME instrument Phase 2 beneficiary:
ADVOS 880349 for device usability improvement, IoT integ…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
